A recent review explores the rapidly expanding field of ferroptosis-based therapy for prostate cancer, presenting ferroptosis as a promising strategy to overcome resistance in advanced and castration-resistant prostate cancer. The authors synthesize current knowledge of ferroptosis mechanisms, biomarkers, therapeutic agents, combination strategies, and translational challenges, proposing a framework that links ferroptosis regulatory networks with precision medicine approaches, according to an Aug. 6 article.
Ferroptosis is described as a distinct form of regulated cell death characterized by iron-dependent lipid peroxidation. Unlike apoptosis, it results from excessive accumulation of reactive oxygen species and oxidative damage to polyunsaturated fatty acid-containing membrane lipids. Prostate cancer cells with metastatic potential appear especially vulnerable to this process.
The review identifies three central components governing ferroptosis: iron metabolism, lipid metabolism, and antioxidant defense systems. It highlights how iron enters cells through transferrin receptor 1 (TFR1), catalyzing reactions that generate highly reactive hydroxyl radicals which initiate oxidation of membrane polyunsaturated fatty acids. Antioxidant systems such as the glutathione-glutathione peroxidase 4 axis work to counterbalance this process.
Lipid metabolism is noted as key in determining sensitivity to ferroptosis. Acyl-CoA synthetase long-chain family member 4 promotes incorporation of polyunsaturated fatty acids into membrane phospholipids, increasing susceptibility to oxidation and cell death. Oncogenic signaling pathways including loss of PTEN or activation of PI3K–AKT–mTOR are also discussed for their roles in promoting resistance or susceptibility to ferroptotic injury.
The tumor immune microenvironment is recognized as an important regulator; activated CD8+ T cells secrete interferon-γ that suppresses SLC7A11 expression and promotes ferroptosis in tumor cells, while M2-polarized macrophages inhibit it through other pathways. The authors highlight several promising biomarkers such as TFR1 and GPX4 that may guide patient selection for future therapies.
While several compounds targeting GPX4 or depleting glutathione show promise in preclinical models—often enhanced when combined with anti-androgen therapies or chemotherapy—the review notes significant challenges remain before clinical translation can occur due to issues like tumor heterogeneity and resistance mechanisms.
